BeiGene’s BRUKINSA gains accelerated FDA approval for follicular lymphoma treatment
In a significant development for patients with relapsed or refractory follicular lymphoma, BeiGene, Ltd. has announced the U.S. Food and Drug Administration (FDA) has granted ... Read More
Lilly announces promising results for Pirtobrutinib Phase 1/2 trials
Eli Lilly's oncology arm, Loxo@Lilly, disclosed that The New England Journal of Medicine (NEJM) has published an extensive analysis of results from the BRUIN Phase ... Read More
Lilly gets Jaypirca FDA approval for mantle cell lymphoma
Loxo@Lilly, the oncology division of Eli Lilly and Company (Lilly), has secured the accelerated approval of the US Food and Drug Administration (FDA) for Jaypirca ... Read More
AbbVie’s ibrutinib, venetoclax combo succeeds in phase 3 GLOW study
AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA (ibrutinib) plus VENCLEXTA/VENCLYXTO (venetoclax) (I+V) has met ... Read More
Sanofi to acquire US biopharma company Principia Biopharma for $3.7bn
Sanofi acquisition of Principia Biopharma : French pharma giant Sanofi has signed an all-cash deal worth $3.68 billion to acquire Principia Biopharma, a late-stage California-based ... Read More
Ascentage, Acerta to evaluate APG-2575, CALQUENCE combo in r/r CLL/SLL
Ascentage Pharma has entered into a clinical collaboration with Acerta Pharma, the hematology research and development center of excellence of AstraZeneca to assess the combination ... Read More
FDA grants accelerated approval to AstraZeneca’s Calquence for mantle cell lymphoma treatment
AstraZeneca has achieved a significant milestone with the early FDA approval of Calquence (acalabrutinib) for the treatment of adult patients with mantle cell lymphoma who ... Read More